secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001628280-24-000480
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead prices 15.79M share offering at $28.50, expects net proceeds of $429.0M
--------------------------------------------------------------------------------

- Sales of 15,790,000 shares at $28.50/share; net proceeds ~$429.0M after discounts and expenses.
- Underwriters include Jefferies, BofA Securities, and Cowen and Company as representatives.
- Proceeds allocated to R&D, general corporate expenses, and working capital needs.
- Offering expected to close on January 5, 2024, subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828024000480/0001628280-24-000480-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828024000480/arwr-20240102.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-000480

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer